[1] Michael C, et al. Safety and Efficacy of Emicizumab in Persons with Hemophilia A With or Without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4) [Abstract #1800] Poster presented at: American Society Of Hematology (ASH) Annual Meeting; 5 -- 8 December, 2020. [2] Shang A, et al. Real-World Safety of Emicizumab: The First Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database [Abstract #2685] Poster presented at: American Society Of Hematology (ASH) Annual Meeting; 5 -- 8 December, 2020. [3]WFH. Guidelines for the management of haemophilia. 2012 [Internet; cited December 2020]. Available from: https://www.globenewswire.com/Tracker?data=AsEXCAS3IHefYQoYMmbbyLkGdiOZgSAfBpCP8o7QkaDwb70U8ing-1gQpxled9dhIJu2QyJXky8VxCiljtZK89sI6qeRik71-A5DSsJu0qWQded7MKx2mJC6pjaUiRffbnz8tXYVvcHjD6NQ-ONbRZQgoKPXjYUL9c_1wigYU1M= http://www1.wfh.org/publications/files/pdf-1472.pdf. [4] Berntorp E, et al. Modern haemophilia care. The Lancet. 2012; 370:1447-1456. [5] Marder VJ, et al. Hemostasis And Thrombosis. 6th ed. Wisconsin. Lippincott Williams & Wilkins; 2013. [6]Franchini M, et al. Haemophilia A in the third millennium. Blood Rev. 2013; 179-84. [7] Gomez K, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014; 12:s319-s329. [8]Whelan SF, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of haemophilia A patients. Blood. 2013; 121:1039-48. Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: https://www.globenewswire.com/Tracker?data=zRFIfwmdj8pr65lcqY-fRMToCU8jM3OaHYRtMoPaSjjkCYvFkZ6sgS1uWvCA3lSv7w2nA-dTEBGe2ipl4ZQ2zOI_A3TiqtmQjXAUUJ-HbrsED4fYleAR9HDw5b8IR9sQ media.relations@roche.com Dr. Nicolas Dunant Patrick Barth Phone: +41 61 687 05 17 Phone: +41 61 688 44 86 Dr. Daniel Grotzky Karsten Kleine Phone: +41 61 688 31 10 Phone: +41 61 682 28 31 Nina Mählitz Nathalie Meetz Phone: +41 79 327 54 74 Phone: +41 61 687 43 05 Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 Roche Investor Relations Dr. Karl Mahler Jon Kaspar Bayard Phone: +41 61 68-78503 Phone: +41 61 68-83894 e-mail: mailto:karl.mahler@roche.com e-mail: mailto:jon_kaspar.bayard@roche.com karl.mahler@roche.com jon_kaspar.bayard@roche.com -------------------------------------------- ------------------------------------------- Dr. Sabine Borngräber Dr. Bruno Eschli Phone: +41 61 68-88027 Phone: +41 61 68-75284 e-mail: mailto:sabine.borngraeber@roche.com e-mail: mailto:bruno.eschli@roche.com sabine.borngraeber@roche.com bruno.eschli@roche.com -------------------------------------------- ------------------------------------------- Dr. Birgit Masjost Dr. Gerard Tobin Phone: +41 61 68-84814 Phone: +41 61 68-72942 e-mail: mailto:birgit.masjost@roche.com e-mail: mailto:gerard.tobin@roche.com birgit.masjost@roche.com gerard.tobin@roche.com -------------------------------------------- ------------------------------------------- Investor Relations North America Loren Kalm Dr. Lisa Tuomi Phone: +1 650 225 3217 Phone: +1 650 467 8737 e-mail: mailto:kalm.loren@gene.com e-mail: mailto:tuomi.lisa@gene.com kalm.loren@gene.com tuomi.lisa@gene.com -------------------------------------------- ------------------------------------------- Attachment -- 07122020_MR_Hemlibra https://ml-eu.globenewswire.com/Resource/Download/c988fa7f-2f2c-4fc3-92e5-3d6916e56eb3
(END) Dow Jones Newswires
December 07, 2020 01:00 ET (06:00 GMT)